LexDanaLexDanabeta
Inventor

Janet A. Takeuchi

Inventor
Anaheim, CA, US

Overview

37→
Patents
2005–2016
Patent span
Chemistry
Primary field (CPC C)

Patents· 37 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations31%
C07DHeterocyclic compounds31%
A61KPreparations for medical, dental or toiletry purposes16%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium14%
C07CAcyclic or carbocyclic compounds8%
PatentTitleYear
9,371,296'Bicyclic 1,3,4-oxadiazole derivatives as sphingosine-1-phosphate receptors\' modulators'20169,120,784'1,3,4-oxadiazoles-2-thio azetidine derivatives as sphingosine-1 phosphate receptors modulators'20159,108,993'Pyrazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators'20159,062,030'Pyrazole azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators'20159,000,016'1,3,4-Oxadiazoles-2-thio derivatives as sphingosine-1 phosphate receptors modulators'20158,987,467'Substituted pyrazole azetidines as sphingosine receptor modulators'20158,987,471'Substituted dihydropyrazoles as sphingosine receptor modulators'20158,957,051'Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators'20158,946,195'Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators'20158,859,598'1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators'20148,846,729'2-thio-1,3,4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators'20148,809,379'Selective subtype alpha 2 adrenergic agents and methods for use thereof'20148,735,399'Selective subtype alpha 2 adrenergic agents and methods for use thereof'20148,729,109'3-(4-(5-phenyl-1 ,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1phosphate receptors modulators'20148,729,110'2-thio-1,3,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators'20148,722,712'Substituted aryl 1 ,2,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators'20148,716,267'Bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators'20148,673,892'Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators'20148,658,623'Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators'20148,658,634'Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators'20148,653,050'Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators'20148,541,582'Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators'20138,513,418'Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators'20138,513,220'Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity'20138,507,685'Phenyl bicyclic methyl azetidine derivatives as sphingosine-1 phosphate receptors modulators'20138,507,686'Substituted bicyclic methyl azetidines as sphingosine-1 phosphate receptors modulators'20138,497,255'Phosphonic acids as S1P receptor modulators'20138,440,698'3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators'20138,362,022'Selective subtype alpha 2 adrenergic agents and methods for use thereof'20138,318,783'3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators'20128,273,776'Biphenyl oxadiazole derivatives as sphingosine-1-phosphate receptors modulators'20128,183,414'N-(1-phenyl-2-arylethyl)-4,5-dihydro-2H-pyrrol-5-amine compounds as subtype selective modulators of ALPHA2B or ALPHA2B and ALPHA2C adrenoceptors'20128,080,570'α2B and α2C agonists'20117,638,648'Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same'20097,468,391'Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B'20087,226,951'Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same'20076,887,896'7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity'2005

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2005–2016Patents assigned to ALLERGAN INC (37)· patent assignee history
2005–2015Based in Anaheim, CA, US· patent location history
2011–2014Patents assigned to LI LING (16)· patent assignee history
2011–2014Patents assigned to TAKEUCHI JANET A (16)· patent assignee history
2011–2014Patents assigned to CHOW KEN (10)· patent assignee history
2013–2014Patents assigned to IM WHA BIN (5)· patent assignee history
2016Based in Irvine, CA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
ALLERGAN INC372005–2016
LI LING162011–2014
TAKEUCHI JANET Aself162011–2014
CHOW KEN102011–2014
IM WHA BIN52013–2014
Locations
LocationPatentsSpan
Anaheim, California, US362005–2015
Irvine, California, US12016